Bork Ulrich, Grützmann Robert, Rahbari Nuh N, Schölch Sebastian, Distler Marius, Reissfelder Christoph, Koch Moritz, Weitz Jürgen
Ulrich Bork, Robert Grützmann, Nuh N Rahbari, Sebastian Schölch, Marius Distler, Christoph Reissfelder, Moritz Koch, Jürgen Weitz, Department of GI, Thoracic and Vascular Surgery, University Hospital Dresden, TU Dresden, 01307 Dresden, Germany.
World J Gastroenterol. 2014 Aug 14;20(30):10296-304. doi: 10.3748/wjg.v20.i30.10296.
Presence of occult minimal residual disease in patients with colorectal cancer (CRC) has a strong prognostic impact on survival. Minimal residual disease plays a major role in disease relapse and formation of metastases in CRC. Analysis of circulating tumor cells (CTC) in the blood is increasingly used in clinical practice for disease monitoring of CRC patients. In this review article the role of CTC, disseminated tumor cells (DTC) in the bone marrow and micrometastases and isolated tumor cells (ITC) in the lymph nodes will be discussed, including literature published until September 2013. Occult disease is a strong prognostic marker for patient survival in CRC and defined by the presence of CTC in the blood, DTC in the bone marrow and/or micrometastases and ITC in the lymph nodes. Minimal residual disease could be used in the future to identify patient groups at risk, who might benefit from individualized treatment options.
结直肠癌(CRC)患者中隐匿性微小残留病的存在对生存具有强烈的预后影响。微小残留病在CRC的疾病复发和转移形成中起主要作用。血液中循环肿瘤细胞(CTC)的分析在临床实践中越来越多地用于CRC患者的疾病监测。在这篇综述文章中,将讨论CTC、骨髓中的播散肿瘤细胞(DTC)和微转移以及淋巴结中的孤立肿瘤细胞(ITC)的作用,包括截至2013年9月发表的文献。隐匿性疾病是CRC患者生存的强有力预后标志物,其定义为血液中存在CTC、骨髓中存在DTC和/或微转移以及淋巴结中存在ITC。微小残留病未来可用于识别有风险的患者群体,这些患者可能从个体化治疗方案中获益。